View More Recent Stories

Apr 11, 2023 09:00AM Belite Bio to Host Key Opinion Leader Webinar on RBP4 Antagonist Tinlarebant in Late-Stage Development for Stargardt Disease 1
Apr 3, 2023 05:37AM Belite Bio (BLTE) Reports FY22, Provides Operational Highlights
Mar 31, 2023 07:03PM Belite Bio Reports Full-Year 2022 Operational Highlights and Financial Results
Mar 31, 2023 07:03PM Belite Bio Reports Full-Year 2022 Operational Highlights and Financial Results
Mar 31, 2023 12:57PM Belite Bio to Host Webcast on April 3, 2023 to Discuss 2022 Full Year Financial Results
Mar 31, 2023 12:57PM Belite Bio to Host Webcast on April 3, 2023 to Discuss 2022 Full Year Financial Results
Nov 18, 2022 08:00AM Belite Bio (BLTE) Finalizes Phase 3 Clinical Trial Plans for LBS-008
Nov 18, 2022 08:00AM Belite Bio Finalizes Phase 3 Clinical Trial Plans for Advanced Dry AMD Treatment with Tinlarebant (LBS-008)
Nov 18, 2022 08:00AM Belite Bio Finalizes Phase 3 Clinical Trial Plans for Advanced Dry AMD Treatment with Tinlarebant (LBS-008)
Oct 20, 2022 08:00AM Belite Bio to Host Key Opinion Leader Webinar on October 27, 2022 to discuss LBS-008 Interim Data
Oct 20, 2022 08:00AM Belite Bio to Host Key Opinion Leader Webinar on October 27, 2022 to discuss LBS-008 Interim Data
Oct 3, 2022 05:53AM Belite Bio (BLTE) Presents 12-Month Interim Results of LBS-008
Oct 1, 2022 07:03PM Belite Bio Presented 12-Month Interim Results of LBS-008 Phase 1b/2 Study in Adolescent Stargardt Disease at AAO Annual Meeting 2022
Oct 1, 2022 07:03PM Belite Bio Presented 12-Month Interim Results of LBS-008 Phase 1b/2 Study in Adolescent Stargardt Disease at AAO Annual Meeting 2022
Sep 23, 2022 08:00AM Belite Bio Announces Late-Breaking Presentation at the American Academy of Ophthalmology 2022 Annual Meeting
Sep 23, 2022 08:00AM Belite Bio Announces Late-Breaking Presentation at the American Academy of Ophthalmology 2022 Annual Meeting
Sep 16, 2022 08:01AM Belite Bio (BLTE) Approved to Conduct LBS-008 Phase 3 Clinical Trial in China
Sep 16, 2022 08:00AM Belite Bio Receives Approval of LBS-008 Phase 3 Clinical Trial in China
Sep 16, 2022 08:00AM Belite Bio Receives Approval of LBS-008 Phase 3 Clinical Trial in China
Aug 22, 2022 08:02AM Belite Bio (BLTE) commenced enrollment for U.S. Phase 3 trial of LBS-008
Aug 22, 2022 08:00AM Belite Bio Initiates Pivotal Phase 3 Clinical Trial of LBS-008 in Stargardt Disease in the U.S.
Aug 22, 2022 08:00AM Belite Bio Initiates Pivotal Phase 3 Clinical Trial of LBS-008 in Stargardt Disease in the U.S.
Aug 10, 2022 09:51PM Belite Bio Reports First Half 2022 Operational Highlights and Financial Results
Aug 10, 2022 09:51PM Belite Bio Reports First Half 2022 Operational Highlights and Financial Results
Aug 1, 2022 04:10PM Belite Bio to Host Conference Call on August 11, 2022 to Discuss First Half 2022 Financial Results
Aug 1, 2022 04:10PM Belite Bio to Host Conference Call on August 11, 2022 to Discuss First Half 2022 Financial Results
Jul 19, 2022 04:06PM Belite Bio (BLTE) Submits IND for Approval to Proceed with LBS-008 Phase 3 Study
Jul 19, 2022 04:05PM Belite Bio Submits Investigational New Drug (IND) Application to FDA for Approval to Proceed with LBS-008 Phase 3 Clinical Trial for the Treatment of Stargardt Disease
Jul 19, 2022 04:05PM Belite Bio Submits Investigational New Drug (IND) Application to FDA for Approval to Proceed with LBS-008 Phase 3 Clinical Trial for the Treatment of Stargardt Disease
May 12, 2022 04:30PM Belite Bio Announces Partial Exercise of Over-Allotment Option in Initial Public Offering
May 12, 2022 04:30PM Belite Bio Announces Partial Exercise of Over-Allotment Option in Initial Public Offering
May 5, 2022 08:01AM Belite Bio (BLTE) Reports Interim Results of LBS-008 Phase 1b/2 Study in Adolescent STGD1
May 5, 2022 08:00AM Belite Bio Presented Interim Results of LBS-008 Phase 1b/2 Study in Adolescent STGD1 at ARVO Annual Meeting 2022
May 5, 2022 08:00AM Belite Bio Presented Interim Results of LBS-008 Phase 1b/2 Study in Adolescent STGD1 at ARVO Annual Meeting 2022
May 3, 2022 04:30PM Belite Bio Announces Closing of $36 Million Initial Public Offering
May 3, 2022 04:30PM Belite Bio Announces Closing of $36 Million Initial Public Offering
May 3, 2022 06:50AM Belite Bio (BLTE) Granted FDA Fast Track Designation For LBS-008
May 3, 2022 06:50AM Belite Bio Receives FDA Fast Track Designation For LBS-008
May 3, 2022 06:50AM Belite Bio Receives FDA Fast Track Designation For LBS-008
Apr 29, 2022 05:58AM Belite Bio, Inc (BLTE) Prices 6M ADS IPO at $6/ADS
Apr 28, 2022 06:58PM Belite Bio Announces Pricing of $36 Million Initial Public Offering
Apr 28, 2022 06:58PM Belite Bio Announces Pricing of $36 Million Initial Public Offering
View More Recent Stories